KeyBanc lowered the firm’s price target on Health Catalyst (HCAT) to $4 from $5 and keeps an Overweight rating on the shares. Ahead of Q3 earnings, the firm believes the setup is mixed across the HCIT landscape. HC Systems are continuing to see elevated utilization, but tech/IT budgets are likely to be challenged by federal funding, KeyBanc notes. The firm believes the Pharma digital advertising environment remains favorable, but sees the bio-pharma funding environment as stagnant, which prolongs any meaningful recovery in spending on R&D software and services. KeyBanc continues to see HCIT platforms than can demonstrate real ROI to clients as faring the best in its coverage.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst Appoints Ben Albert as New President
- Health Catalyst names Ben Albert as COO
- Health Catalyst expands partnership with CyncHealth Nebraska
- Cautious Hold Rating on Health Catalyst Amid Regulatory and Transition Challenges
- Health Catalyst: Strong Buy Rating Amidst Long-Term Growth Prospects and Industry Leadership